Imatinib, a first-generation tyrosine kinase inhibitor (TKI) that is also marketed under the names Gleevac and STI571, reduced BCR-ABL and slowed the course of CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.